Elinzanetant Outcomes from the OASIS 1 and 2 Phase 3 Trials: A Read Out with Lead Investigator JoAnn Pinkerton, MD

“The very rapid reduction of hot flushes seen with elinzanetant—within 1 week of initiating treatment—is very exciting. And that decline continued until the medicine was stopped. With HRT you might not see a strong benefit until 4 to 8 weeks.”

Elinzanetant, a novel dual neurokinin-1,3 (NK-1, NK-3) receptor antagonist, met all key primary and secondary endpoints in the pivotal OASIS 1 and OASIS 2 phase 3 clinical trials, demonstrating statistically significant reductions in the frequency and severity of moderate to severe vasomotor symptoms (VMS) associated with menopause. The findings were announced at the 2024 American College of Obstetricians and Gynecologists annual meeting where lead investigator JoAnn Pinkerton, MD, presented the final data. Pinkerton highlighted the notable results and detailed the benefits of dual neurokinin inhibition in a recent interview with Patient Care.®

JoAnn Pinkerton, MD, is professor of obstetrics and gynecology and division director Midlife Health at the University of Virginia Health System in Charlottesville, Virginia. Dr Pinkerton is the national lead for the elinzanetant OASIS clinical trial program.